|Bid||1.4400 x 1000|
|Ask||1.4500 x 3200|
|Day's Range||1.3700 - 1.4599|
|52 Week Range||1.0400 - 3.0200|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.61|
Subscribe to Yahoo Finance Plus to view Fair Value for CTMX
Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.
Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.